WO2001085183A2 - Preparation for the prevention and treatment of ocular disorders - Google Patents

Preparation for the prevention and treatment of ocular disorders Download PDF

Info

Publication number
WO2001085183A2
WO2001085183A2 PCT/NL2001/000348 NL0100348W WO0185183A2 WO 2001085183 A2 WO2001085183 A2 WO 2001085183A2 NL 0100348 W NL0100348 W NL 0100348W WO 0185183 A2 WO0185183 A2 WO 0185183A2
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
extract
component
prevention
treatment
Prior art date
Application number
PCT/NL2001/000348
Other languages
French (fr)
Other versions
WO2001085183A3 (en
Inventor
Peter Julien Edward Verdegem
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Priority to AU2001256855A priority Critical patent/AU2001256855A1/en
Publication of WO2001085183A2 publication Critical patent/WO2001085183A2/en
Publication of WO2001085183A3 publication Critical patent/WO2001085183A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Definitions

  • the present invention relates to a preparation for the prevention and/or treatment of ocular disorders, in particular cataracts, age-related macula degeneration (AMD) and glaucoma.
  • ocular disorders in particular cataracts, age-related macula degeneration (AMD) and glaucoma.
  • Cataracts are opacities of the lens and the onset of the disorder in patients is usually above 50 years of age.
  • the opacities in the lens are aggregates of damaged and hence dysfunctional lens proteins, predominantly crystallines.
  • Two mechanisms are responsible for the damage inflicted on the crystallines: oxidative stress, leading to destruction of the proteins, and high glucose or sorbitol levels of the lens, causing glycosilation of the crystallines, making them dysfunctional.
  • Age related macula degeneration is a degenerative disorder of the macula lutea or yellow spot, which is the central part of the retina, with the highest visual acuity and concentration of cones.
  • Two forms of AMD can be discriminated.
  • Dry AMD or atrophic AMD is characterized by hard or soft drusen (deposits of cellular debris), changes in the retinal pig- ment epithelium or atrophy of the photoreceptors and the retinal pigment epithelium.
  • Wet AMD is a more advanced form of AMD and is characterized by neovascularization and exudation of fluid.
  • Two pigments are present in the macula and are responsible for its characteristic yellow color: lutein and zeaxanthin.
  • Glaucoma is a collection of disorders which is caused by an increased intra ocular pressure (IOP). This pressure causes ische ic insults to the retina and irreversible damage to the ocular nerve.
  • IOP intra ocular pressure
  • the present invention provides a preparation for the prevention and/or treatment of ocular disorders which comprises a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood flow.
  • the aldose reductase inhibitor limits the reduction of glucose to sorbitol.
  • this component is a Chrysanthemum morifolium, Bixa orellana, Ipomoea batatas, Vaccinium myrtillus, Buddleia officinalis, Cistancha salsa or Glycyrhizza glabra extract.
  • Extracts from Chrysanthemum morifolium are flower extracts and should certainly comprise acacetin, diosmetin, luteoline or their glucosides and/or ellagic acid.
  • the extract is prepared such that it contains 0.25 wt.% chlorogenic acid.
  • Extracts from Bixa orellana should certainly comprise gallic acid and/or pyrogallol.
  • Extracts from Ipomoea batatas should certainly comprise scopoletin and/or caffeic acid.
  • Extracts of Vaccinium myrtillus axe berry extracts and contain preferably at least 25 wt.% anthocyanosides (based on dry matter).
  • the extract of Buddleia officinalis is preferably an alcohol/water extract of the flower bud.
  • Such extracts can be obtained from the firm KING HERB.
  • the extract of Cistancha salsa is preferably an alcohol/water extract of the stem, also available from KING HERB.
  • the extract of Glycyrhizza glabra is preferably an extract containing at least 12.7 wt.% glycyrrhizic acid. It can be obtained from ZANDU.
  • Suitability of the plant (extracts) as aldose reductase inhibitors for the object of the invention can also be determined by means of the assay as described in the examples hereafter.
  • the extract should have an LC 5 o of 0.03 mg/ml at the most.
  • the aldose reductase inhibitor comprises preferably at least a component selected from the group consisting of acacetin, diosmetin, luteoline, ellagic acid, gallic acid, pyrogallol, isoscutellarein, scopoletin, 3,5-dicaffeoylquinic acid and caffeic acid or their functional analogues, said functional analogues being glucosides, esters or salts thereof.
  • one or more of these components are preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.
  • the intra ocular pressure lowering component is a component selected from the group catechins, flavonoids and/or tannins.
  • catechins and most preferably in the form of a green tea extract is used, i.e. an extract rich in epigallocatechin or epigallocatechin gallate.
  • Component b is alternatively myrecetin, quercetin or tannin.
  • Component b is preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.
  • Component c the component that increases ocular blood flow is an isoflavon or a water soluble carotenoid.
  • the isoflavon is preferably puerarin or an equivalent thereof. This isoflavon can be extracted from the roots of Pueraria lobata, also known as kudzu. This extract is traditionally used to assist in alcohol withdrawal support and to prevent or treat angina and high blood pressure.
  • the water soluble carotenoid is preferably crocetin or crocin or an equivalent thereof.
  • Component c is preferably administered in a daily dose of 0.01 to 50 mg/day, preferably 0.1 to 10 mg/day.
  • the preparation of the invention can further contain, beside the above mentioned components a, b and c, lutein, zeaxanthine and/or one or more antioxidant.
  • Lutein and zeaxanthine can be present in an amount of 0.01 to 50 mg/day, preferably 0.1 to 20 mg/day.
  • lutein is included, in particular as a stable and readily absorbable form, such as a lutein ester.
  • Antioxidants can be vitamin C, vitamin E, zinc, ⁇ -carotene, copper, and selenium.
  • An extract with antioxidant activity is for instance bilberry extract.
  • the preparation can also contain one or more of vitamin A, ribofiavin, gingko biloba, N- acetylcysteine, vitamin B6, vitamin B12 and folic acid.
  • the preparation of the invention can be used in the treatment and/or prevention of ocular disorders, in particular in the treatment or prevention of cataracts, age related macula degeneration and glaucoma.
  • the preparation of the invention is a pharmaceutical or dietary preparation, in particular a nutritional supplement.
  • the nutritional supplement that is administered on a daily basis to prevent the ocular disorders.
  • Such a supplement can have the form of a tablet, drink, powder, bar, cookie, cereal, etc., as is known to the skilled person. Also foods which contain the above ingredients are possible.
  • Dl-glyceraldehyde which is used as a model system for glucose (Dufrane, et al 1984), aldose reductase, obtained from rat lenses (Inuma et al 1989) and NADPH are incubated at 37 °C. The absorption of NADPH at 340 nm is spectrophotometrically followed for 15 minutes. This decay is proportional to the enzyme activity of aldose reductase, since NADPH and glyceraldehyde react stoechiometrically.
  • the % inhibition of different sample concentrations can than be calculated with differences in the slopes between sample and blank (without sample).
  • the LC 5 o value can be calculated.
  • the LC 5 o value is defined as that concentration of the sample that inhibits aldose reductase with 50%.
  • the data for the herbal extracts was compared to quercitrin, a standard commonly used in aldose reductase inhibition assays.
  • the LC 5 o values for the samples are listed in Table 1.
  • composition of the preparation is:
  • Pueraria Root extract 5 % 50 mg

Abstract

The present invention relates to a preparation for the prevention and/or treatment of ocular disorders which comprises: a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood flow. Component a can be Chrysantemum morifolium, Bixa orellana, Ipomoea batatas Vaccinium myrtillus, Buddleia officinalis, Cistancha salsa or Glycyrhizza glabra extract. Component b can be a green tea extract, myrecetin, querecetin or tannin. Component c can be an isoflavon or a water soluble carotenoid.

Description

Preparation for the prevention and treatment of ocular disorders
The present invention relates to a preparation for the prevention and/or treatment of ocular disorders, in particular cataracts, age-related macula degeneration (AMD) and glaucoma.
Cataracts are opacities of the lens and the onset of the disorder in patients is usually above 50 years of age. The opacities in the lens are aggregates of damaged and hence dysfunctional lens proteins, predominantly crystallines. Two mechanisms are responsible for the damage inflicted on the crystallines: oxidative stress, leading to destruction of the proteins, and high glucose or sorbitol levels of the lens, causing glycosilation of the crystallines, making them dysfunctional.
Excessive exposure of the lens to sunlight, nutrition status and smoking are the main risk factors for oxidative stress of the lens. High glucose and sorbitol levels have been established with diabetes patients. Current methods for the treatment of cataracts include lens extraction, costing about $3.5 billion annually in the USA. Existing nutritional supplement formulae for the prevention of cataracts are usually based on antioxidants (vitamin E, vitamin C, β-caro- tene) and minerals that support antioxidant proteins (Zn, Se).
Age related macula degeneration (AMD) is a degenerative disorder of the macula lutea or yellow spot, which is the central part of the retina, with the highest visual acuity and concentration of cones. Two forms of AMD can be discriminated. Dry AMD or atrophic AMD is characterized by hard or soft drusen (deposits of cellular debris), changes in the retinal pig- ment epithelium or atrophy of the photoreceptors and the retinal pigment epithelium. Wet AMD is a more advanced form of AMD and is characterized by neovascularization and exudation of fluid. Two pigments are present in the macula and are responsible for its characteristic yellow color: lutein and zeaxanthin. These water soluble carotenoids are thought to protect the macula by absorbing high energy blue light and by their antioxidant properties. The macula is avascular and depends therefor on the choroid, which is the layer in the eye behind the retina, for its nutrient supply. Current supplement prevention formulae include mostly antioxidants and lutein. Glaucoma is a collection of disorders which is caused by an increased intra ocular pressure (IOP). This pressure causes ische ic insults to the retina and irreversible damage to the ocular nerve. Common supplements for the prevention of glaucoma are based on antioxidants.
In view of the wide spread occurrence of the above mentioned disorders, there is a need for a preparation that can prevent or treat these disorders simultaneously. The present inventors have now found such a preparation that is particularly active against the above three disorders, cataracts, age related macula degeneration and glaucoma.
The present invention provides a preparation for the prevention and/or treatment of ocular disorders which comprises a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood flow.
Component a, the aldose reductase inhibitor limits the reduction of glucose to sorbitol. Preferably this component is a Chrysanthemum morifolium, Bixa orellana, Ipomoea batatas, Vaccinium myrtillus, Buddleia officinalis, Cistancha salsa or Glycyrhizza glabra extract.
Extracts from Chrysanthemum morifolium are flower extracts and should certainly comprise acacetin, diosmetin, luteoline or their glucosides and/or ellagic acid. The extract is prepared such that it contains 0.25 wt.% chlorogenic acid. Extracts from Bixa orellana should certainly comprise gallic acid and/or pyrogallol. Extracts from Ipomoea batatas should certainly comprise scopoletin and/or caffeic acid. Extracts of Vaccinium myrtillus axe berry extracts and contain preferably at least 25 wt.% anthocyanosides (based on dry matter). The extract of Buddleia officinalis is preferably an alcohol/water extract of the flower bud. Such extracts can be obtained from the firm KING HERB. The extract of Cistancha salsa is preferably an alcohol/water extract of the stem, also available from KING HERB. The extract of Glycyrhizza glabra is preferably an extract containing at least 12.7 wt.% glycyrrhizic acid. It can be obtained from ZANDU. Suitability of the plant (extracts) as aldose reductase inhibitors for the object of the invention can also be determined by means of the assay as described in the examples hereafter. The extract should have an LC5o of 0.03 mg/ml at the most.
Consequently, according to the invention, the aldose reductase inhibitor comprises preferably at least a component selected from the group consisting of acacetin, diosmetin, luteoline, ellagic acid, gallic acid, pyrogallol, isoscutellarein, scopoletin, 3,5-dicaffeoylquinic acid and caffeic acid or their functional analogues, said functional analogues being glucosides, esters or salts thereof.
Preferably one or more of these components, in synthetic form but most preferably as extract, are preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.
Component b, the intra ocular pressure lowering component is a component selected from the group catechins, flavonoids and/or tannins. Preferably catechins, and most preferably in the form of a green tea extract is used, i.e. an extract rich in epigallocatechin or epigallocatechin gallate. Component b is alternatively myrecetin, quercetin or tannin. Component b is preferably administered in a daily dose of 0.01 to 100 mg/day, preferably 1 to 50 mg/day.
Component c, the component that increases ocular blood flow is an isoflavon or a water soluble carotenoid. The isoflavon is preferably puerarin or an equivalent thereof. This isoflavon can be extracted from the roots of Pueraria lobata, also known as kudzu. This extract is traditionally used to assist in alcohol withdrawal support and to prevent or treat angina and high blood pressure. The water soluble carotenoid is preferably crocetin or crocin or an equivalent thereof. Component c is preferably administered in a daily dose of 0.01 to 50 mg/day, preferably 0.1 to 10 mg/day.
The preparation of the invention can further contain, beside the above mentioned components a, b and c, lutein, zeaxanthine and/or one or more antioxidant. Lutein and zeaxanthine can be present in an amount of 0.01 to 50 mg/day, preferably 0.1 to 20 mg/day. Preferably lutein is included, in particular as a stable and readily absorbable form, such as a lutein ester. Antioxidants can be vitamin C, vitamin E, zinc, β-carotene, copper, and selenium. An extract with antioxidant activity is for instance bilberry extract.
The preparation can also contain one or more of vitamin A, ribofiavin, gingko biloba, N- acetylcysteine, vitamin B6, vitamin B12 and folic acid.
The preparation of the invention can be used in the treatment and/or prevention of ocular disorders, in particular in the treatment or prevention of cataracts, age related macula degeneration and glaucoma.
The preparation of the invention is a pharmaceutical or dietary preparation, in particular a nutritional supplement. The nutritional supplement that is administered on a daily basis to prevent the ocular disorders. Such a supplement can have the form of a tablet, drink, powder, bar, cookie, cereal, etc., as is known to the skilled person. Also foods which contain the above ingredients are possible.
Examples
Assay aldose reductase inhibition
The inhibitory effects of herbal extracts towards aldose reductase are assessed with the following in vitro assay.
Dl-glyceraldehyde, which is used as a model system for glucose (Dufrane, et al 1984), aldose reductase, obtained from rat lenses (Inuma et al 1989) and NADPH are incubated at 37 °C. The absorption of NADPH at 340 nm is spectrophotometrically followed for 15 minutes. This decay is proportional to the enzyme activity of aldose reductase, since NADPH and glyceraldehyde react stoechiometrically.
The % inhibition of different sample concentrations can than be calculated with differences in the slopes between sample and blank (without sample). By linearization of the dose response curve (% inhibition in probit against log concentration) the LC5o value can be calculated. The LC5o value is defined as that concentration of the sample that inhibits aldose reductase with 50%. The data for the herbal extracts was compared to quercitrin, a standard commonly used in aldose reductase inhibition assays. The LC5o values for the samples are listed in Table 1.
Table 1
Figure imgf000006_0001
Formulation example
An example composition of the preparation is:
Pueraria Root extract 5 % 50 mg
Green Tea extract 80 % polyphenols 20 mg
Chrysanthemum morifolium extract 4:1 20 mg
Vitamin A 2500 IU
Beta-carotene 2500 IU
Lutein 10 mg
Riboflavin 5 mg
Vitamin C 600 mg
Vitamin E 220 IU
Zinc 15 mg
Copper 3 mg
Selenium 70 μg
Bilberry extract 200 mg
Gingko biloba 30 mg
N-acetylcysteine 200 mg
Vitamin B6 4 mg
Vitamin B12 4 μg
Folic acid 600 μg

Claims

Claims
1. Preparation for the prevention and or treatment of ocular disorders which comprises a. an aldose reductase inhibitor; b. an intra ocular pressure lowering component; and c. a component that increases ocular blood flow.
2. Preparation according to claim 1, wherein the aldose reductase inhibitor is a Chrysan- themum morifolium, Bixa orellana Ipomoea batatas, Vaccinium myrtillus, Buddleia officinalis, Cistancha salsa or Glycyrhizza glabra extract.
3. Preparation according to claim 2, wherein the extract from Chrysanthemum morifolium comprises acacetin, diosmetin, luteoline or their glucosides and/or ellagic acid.
4. Preparation according to claim 2, wherein the extract from Bixa orellana comprises gallic acid and/or pyrogallol.
5. Preparation according to claim 2, wherein the extract from Ipomoea batatus comprises scopoletin and/or caffeic acid.
6. Preparation according to claim 1, wherein the aldose reductase inhibitor comprises at least a component selected from the group consisting of acacetin, diosmetin, luteoline, ellagic acid, gallic acid, pyrogallol, isoscutellarein, scopoletin, 3,5-dicaffeoylquinic acid and caffeic acid or their functional analogues, said functional analogues being glucosides, esters or salts thereof.
7. Preparation according to any of the preceding claims, wherein the aldose reductase inhibitor is a Chrysanthemum morifolium extract.
8. Preparation according to any of claims 1 to 7, wherein the intra ocular pressure lowering component is a green tea extract.
9. Preparation according to claim 8, wherein the intra ocular pressure lowering component is a catechin, in particular epigallocatechin or epigallocatechin gallate.
10. Preparation according to any of claims 1 to 7, wherein the intra ocular pressure lowering component is myrecetin, quercetin or tannin.
11. Preparation according to any of claims 1 to 10, wherein the component that increases ocular blood flow is an isoflavon or a water soluble carotenoid.
12. Preparation according to claim 11, wherein the isoflavon is puerarin.
13. Preparation according to claim 11, wherein the water soluble carotenoid is crocetin or crocin.
14. Preparation according to any of the preceding claims, comprising a. Chrysanthemum morifolium extract; b. green tea extract; and c. puerarin.
15. Preparation according to any of claims 1 to 14, further comprising lutein.
16. Preparation according to any of claims 1 to 15, further comprising one or more antioxidants.
17. Use of a preparation according to any of claims 1 to 16 for the treatment and/or prevention of ocular disorders.
18. Use of a preparation according to any of claims 1 to 16 for the treatment and/or prevention of cataracts.
19. Use of a preparation according to any of claims 1 to 16 for the treatment and/or prevention of age related macula degeneration.
20. Preparation according to any of claims 1 to 16 for the treatment and/or prevention of glaucoma.
PCT/NL2001/000348 2000-05-08 2001-05-08 Preparation for the prevention and treatment of ocular disorders WO2001085183A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256855A AU2001256855A1 (en) 2000-05-08 2001-05-08 Preparation for the prevention and treatment of ocular disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56638500A 2000-05-08 2000-05-08
US09/566,385 2000-05-08

Publications (2)

Publication Number Publication Date
WO2001085183A2 true WO2001085183A2 (en) 2001-11-15
WO2001085183A3 WO2001085183A3 (en) 2002-08-15

Family

ID=24262669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2001/000348 WO2001085183A2 (en) 2000-05-08 2001-05-08 Preparation for the prevention and treatment of ocular disorders

Country Status (2)

Country Link
AU (1) AU2001256855A1 (en)
WO (1) WO2001085183A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005827A2 (en) * 2000-07-18 2002-01-24 Forum Bioscience Use of natural products in cancer treatment
EP1354594A1 (en) * 2002-04-17 2003-10-22 Cognis Iberia, S.L. Combinations of an extract of a vaccinium type plant and a carotene
WO2004012522A1 (en) * 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
DE10357046A1 (en) * 2003-12-04 2005-06-30 Beiersdorf Ag Cosmetic or dermatological preparations containing a combination of green dye and anti-inflammatory agent
WO2007141898A1 (en) * 2006-06-02 2007-12-13 Riken Vitamin Co., Ltd. Ameliorant for eye strain
US20100216856A1 (en) * 2007-01-31 2010-08-26 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
CN102492008A (en) * 2011-12-12 2012-06-13 中国医学科学院药用植物研究所 Active extract containing isocarthamidin 7-O-beta-D-glucuronidase and use thereof
CN102491964A (en) * 2011-12-11 2012-06-13 卞毓平 Method for extracting acacetin from chrysanthemum
CN102526341A (en) * 2012-01-17 2012-07-04 宁夏医科大学 Chinese medicine for treating and relaying age-related cataract advancement
CN102670748A (en) * 2012-05-29 2012-09-19 刘雁 Chinese medicine for treating acute glaucom
FR2975008A1 (en) * 2011-05-13 2012-11-16 Inst Biophytis USE OF COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
CN103494853A (en) * 2013-09-18 2014-01-08 安徽盛海堂中药饮片有限公司 Industrial extraction method for Bozhou chrysanthemum flowers
WO2016174360A1 (en) * 2015-04-30 2016-11-03 Biophytis Composition containing norbixin for protecting cells of the retinal pigment epithelium
CZ308039B6 (en) * 2017-10-19 2019-11-13 Centrum organické chemie s.r.o. Stable aqueous antimicrobial dispersion, use of this dispersion, cosmetic emulsion and coating composition containing this dispersion
CN110934860A (en) * 2019-12-23 2020-03-31 辽宁大学 Application of luteolin in preparation of medicine for inhibiting retinopathy
JP2022028067A (en) * 2020-07-08 2022-02-14 株式会社東洋新薬 Retina protective composition

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906761A2 (en) * 1997-10-02 1999-04-07 Archer-Daniels-Midland Company Method of preparing and using phytochemicals
WO1999038497A2 (en) * 1998-01-30 1999-08-05 R-Tech Ueno, Ltd. Ophthalmic composition
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
EP0968709A1 (en) * 1998-07-03 2000-01-05 Lanatech Laboratoire Nature et Technique Cosmetic composition having antiradical synergistic effect
DE19950327A1 (en) * 1998-10-19 2000-04-20 Werklust & Beheer Wassenaar B Use of carotenoid ester compounds, especially derived from lutein and zeaxanthin, in prevention and treatment of eye disorders, especially age-related macular degeneration and cataract
WO2000059523A1 (en) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
CN1291495A (en) * 2000-09-01 2001-04-18 唐秀君 Health-care vision-improving tea
WO2001078783A2 (en) * 2000-04-17 2001-10-25 Hauser, Inc. Compositions comprising natural agents for treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3625373B2 (en) * 1998-04-07 2005-03-02 株式会社ノエビア Topical skin preparation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906761A2 (en) * 1997-10-02 1999-04-07 Archer-Daniels-Midland Company Method of preparing and using phytochemicals
WO1999038497A2 (en) * 1998-01-30 1999-08-05 R-Tech Ueno, Ltd. Ophthalmic composition
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
EP0968709A1 (en) * 1998-07-03 2000-01-05 Lanatech Laboratoire Nature et Technique Cosmetic composition having antiradical synergistic effect
DE19950327A1 (en) * 1998-10-19 2000-04-20 Werklust & Beheer Wassenaar B Use of carotenoid ester compounds, especially derived from lutein and zeaxanthin, in prevention and treatment of eye disorders, especially age-related macular degeneration and cataract
WO2000059523A1 (en) * 1999-04-08 2000-10-12 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
WO2001078783A2 (en) * 2000-04-17 2001-10-25 Hauser, Inc. Compositions comprising natural agents for treatment of cancer
CN1291495A (en) * 2000-09-01 2001-04-18 唐秀君 Health-care vision-improving tea

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HODGES L C ET AL: "INTRAOCULAR PRESSURE-LOWERING ACTIVITY OF PHENOLIC ANTIOXIDANTS IN NORMOTENSIVE RABBITS" CURRENT EYE RESEARCH, IRL PRESS, OXFORD, GB, vol. 19, no. 3, September 1999 (1999-09), pages 234-240, XP000978437 ISSN: 0271-3683 *
JOUSSEN ANTONIA M ET AL: "Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids." EXPERIMENTAL EYE RESEARCH, vol. 71, no. 5, November 2000 (2000-11), pages 483-487, XP001070101 ISSN: 0014-4835 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 01, 31 January 2000 (2000-01-31) & JP 11 292785 A (NOEVIR CO LTD), 26 October 1999 (1999-10-26) *
SRIVASTAVA ANIL ET AL: "Chemistry, pharmacology and uses of Bixa orellana: A review." JOURNAL OF MEDICINAL AND AROMATIC PLANT SCIENCES, vol. 21, no. 4, December 1999 (1999-12), pages 1145-1154, XP001070002 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005827A2 (en) * 2000-07-18 2002-01-24 Forum Bioscience Use of natural products in cancer treatment
WO2002005827A3 (en) * 2000-07-18 2002-07-18 Forum Bioscience Use of natural products in cancer treatment
EP1354594A1 (en) * 2002-04-17 2003-10-22 Cognis Iberia, S.L. Combinations of an extract of a vaccinium type plant and a carotene
WO2003086428A1 (en) * 2002-04-17 2003-10-23 Cognis Iberia, S.L. Active substance mixtures of extracts of the genus vaccinium and carotene compounds
WO2004012522A1 (en) * 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
DE10357046A1 (en) * 2003-12-04 2005-06-30 Beiersdorf Ag Cosmetic or dermatological preparations containing a combination of green dye and anti-inflammatory agent
US11497942B2 (en) 2003-12-04 2022-11-15 Beiersdorf Ag Cosmetic or dermatological preparation comprising a combination of a dye and an anti-inflammatory active ingredient
WO2007141898A1 (en) * 2006-06-02 2007-12-13 Riken Vitamin Co., Ltd. Ameliorant for eye strain
US20100216856A1 (en) * 2007-01-31 2010-08-26 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
US8536212B2 (en) * 2007-01-31 2013-09-17 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
FR2975008A1 (en) * 2011-05-13 2012-11-16 Inst Biophytis USE OF COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
US20170354638A1 (en) * 2011-05-13 2017-12-14 Biophytis Bixa orellana composition for the treatment macular degeneration
WO2012156600A1 (en) 2011-05-13 2012-11-22 Institut Biophytis Sas Bixa orellana composition for treating macular degeneration
JP2014514366A (en) * 2011-05-13 2014-06-19 アンスティチュ・ビオフィティス・エスアーエス A composition derived from rye olera for the treatment of macular degeneration
US20140322371A1 (en) * 2011-05-13 2014-10-30 Stanislas Veillet Bixa orellana composition for treating macular degeneration
CN102491964B (en) * 2011-12-11 2013-08-21 湖北诺克特药业有限公司 Method for extracting acacetin from chrysanthemum
CN102491964A (en) * 2011-12-11 2012-06-13 卞毓平 Method for extracting acacetin from chrysanthemum
CN102492008A (en) * 2011-12-12 2012-06-13 中国医学科学院药用植物研究所 Active extract containing isocarthamidin 7-O-beta-D-glucuronidase and use thereof
CN102526341A (en) * 2012-01-17 2012-07-04 宁夏医科大学 Chinese medicine for treating and relaying age-related cataract advancement
CN102670748A (en) * 2012-05-29 2012-09-19 刘雁 Chinese medicine for treating acute glaucom
CN103494853A (en) * 2013-09-18 2014-01-08 安徽盛海堂中药饮片有限公司 Industrial extraction method for Bozhou chrysanthemum flowers
WO2016174360A1 (en) * 2015-04-30 2016-11-03 Biophytis Composition containing norbixin for protecting cells of the retinal pigment epithelium
US10314804B2 (en) 2015-04-30 2019-06-11 Biophytis Composition containing norbixin for protecting cells of the retinal pigment epithelium
FR3035589A1 (en) * 2015-04-30 2016-11-04 Inst Biophytis COMPOSITION FOR THE PROTECTION OF RETINAL PIGMENTARY EPITHELIUM CELLS
CZ308039B6 (en) * 2017-10-19 2019-11-13 Centrum organické chemie s.r.o. Stable aqueous antimicrobial dispersion, use of this dispersion, cosmetic emulsion and coating composition containing this dispersion
CN110934860A (en) * 2019-12-23 2020-03-31 辽宁大学 Application of luteolin in preparation of medicine for inhibiting retinopathy
JP2022028067A (en) * 2020-07-08 2022-02-14 株式会社東洋新薬 Retina protective composition

Also Published As

Publication number Publication date
AU2001256855A1 (en) 2001-11-20
WO2001085183A3 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
WO2001085183A2 (en) Preparation for the prevention and treatment of ocular disorders
Rodríguez et al. Changes in bioactive components and antioxidant capacity of maqui, Aristotelia chilensis [Mol] Stuntz, berries during drying
Smeriglio et al. Polyphenolic profile and biological activities of black carrot crude extract (Daucus carota L. ssp. sativus var. atrorubens Alef.)
Suryanarayana et al. Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract
Rosenblat et al. Antioxidative properties of pomegranate: in vitro studies
Kaur et al. Nutraceuticals in prevention of cataract–An evidence based approach
US8591964B2 (en) Vaccinium species compositions
Ajuwon et al. Protective effects of rooibos (Aspalathus linearis) and/or red palm oil (Elaeis guineensis) supplementation on tert-butyl hydroperoxide-induced oxidative hepatotoxicity in Wistar rats
Yahia et al. Nutritional and health-promoting properties of tropical and subtropical fruits
Jadhav et al. Free radical scavenging and antioxidant activity of Punica granatum Linn
US6572897B1 (en) Insulin sensitivity maintenance and blood sugar level maintenance formulation for the prevention and treatment of diabetes
WO2010146577A1 (en) Edible products with thermostatic and cognitive effects
Zebua et al. Hypoglicemic activity of gambier (Uncaria gambir robx.) drinks in alloxan-induced mice
AU2006347125B2 (en) Antioxidant composition containing component originating in the bark of tree belonging to the genus Acacia
KR100815278B1 (en) Composition of healthy food for preventing oxidative damage of eye
Yusuf et al. Identifications of polyphenols and α-amylase inhibitory activity of multi herbal formulation: Cocoa beans (Theobroma cocoa), buni (Antidesma bunius L. Spreng) and cinnamons (Cinnamomum cassia)
EP1785040A1 (en) Body fat-reducing agent
Barden et al. Effect of grape polyphenols on oxidative stress in canine lens epithelial cells
Osorio et al. Golden berry and selected tropical (açai, acerola and maqui) juices
Lim Opuntia ficus-indica
Benzie et al. Bioavailability of antioxidant compounds from fruits
Butt et al. Health benefits of anthocyanins in black carrot (Daucus carota)
LIAOTRAKOON et al. Antioxidative properties of white and red flowered agathi (Sesbania grandiflora) tea and tea extracts
KR100690071B1 (en) Functional composition for the prevention and improvement of hangover
Greenway et al. Fruit and vegetable micronutrients in diseases of the eye

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP